IVIXF (Invion) 10-Year Sharpe Ratio: 0.50 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVIXF Invion Ltd IVIXF
16 GF Score
Price $0.04
! 8 Warning Signs
View Full Analysis

What is Invion 10-Year Sharpe Ratio?

Invion IVIXF -83.23% 16 10-Year Sharpe Ratio is 0.50 as of Sep. 22, 2026. GuruFocus rates IVIXF with a GF Score™ of 16/100. The stock has 8 warning signs investors should review.

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2026-09-22), Invion's 10-Year Sharpe Ratio is 0.50.

Invion  (OTCPK:IVIXF) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Invion 10-Year Sharpe Ratio Related Terms

IVIXF vs ZTS: 10-Year Sharpe Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Invion's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invion 10-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invion's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Invion's 10-Year Sharpe Ratio falls into.


IVIXF
16GF Score
Invion Ltd IVIXF
10-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invion 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.

Frequently Asked Questions Learn more about 10-Year Sharpe Ratio →
What does a 10-Year Sharpe Ratio of 0.50 mean?
Invion (IVIXF) has a 10-Year Sharpe Ratio of 0.50 as of Sep. 22, 2026. 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. View historical data for Invion and its competitors.
Is Invion's 10-Year Sharpe Ratio too high?
Invion's current 10-Year Sharpe Ratio is 0.50. Overall, Invion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Invion's 10-Year Sharpe Ratio compare to ZTS?
Invion's 10-Year Sharpe Ratio of 0.50 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Sharpe Ratio for a Drug Manufacturers company?
A good 10-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 10-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Sharpe Ratio mean?
A high 10-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. View historical data for Invion and its competitors. Invion's current 10-Year Sharpe Ratio is 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Invion (IVIXF) has a current 10-Year Sharpe Ratio of 0.50. The current 10-Year Sharpe Ratio is 0.50. Invion's overall GF Score™ is 16/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Sharpe Ratio calculated?
10-Year Sharpe Ratio is calculated from a company's financial statements. For Invion (IVIXF), the current 10-Year Sharpe Ratio is 0.50 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invion Business Description

Other Exchanges 7C8:GermanyIVX:Australia
Address 692 High Street, East Kew, VIC, AUS, 3102
Invion Ltd is an Australian clinical-stage life-science company focused on developing photodynamic therapy (PDT) treatments. Its core technology, Photosoft, is a photosensitiser activated by light to destroy cancer cells and pathogens. Invion holds a perpetual, exclusive, worldwide licence to Photosoft, giving it rights to develop, manufacture, market, distribute, sub-license and commercialise the technology across a portfolio of agreed indications in both human and animal health. The company is advancing Photosoft through clinical trials for a range of cancers and infectious diseases, targeting areas of unmet medical need. As a clinical-stage business, Invion does not yet generate product revenue; its activities are funded through capital raising and it operates as a single reporting segment. Its focus is on progressing its pipeline toward regulatory approval and commercialisation, potentially through partnerships or licensing arrangements with larger pharmaceutical or animal-health companies.
16GF Score

Get the complete analysis for IVIXF

10-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price